Boston, MA, United States
Boston, MA, United States

Time filter

Source Type

Attendees in Boston will see demonstrations of Aixplorer with real-time ShearWave Elastography™ and several clinical research abstracts on its use for liver stiffness measurement AIX-EN-PROVENCE, FRANCE--(Marketwired - Nov 10, 2016) - SuperSonic Imagine ( : SSI) (FR0010526814), a company specializing in ultrasound medical imaging, announced today that it will feature Aixplorer with real-time ShearWave Elastography (SWE™) at The Liver Meeting 2016 November 11 - 15 in Boston. The Company will be exhibiting in conjunction with Sandhill Scientific, Inc., their exclusive distributor in the United States for providing the Aixplorer® ultrasound system to Gastroenterologists and Hepatologists. Attendees of this meeting, held by the American Association for the Study of Liver Diseases (AASLD), will have the opportunity to learn more about SWE's value to patients with chronic liver disease. Real-time ShearWave Elastography (SWE), available only on the Aixplorer ultrasound system, is a 60-second non-invasive exam that can be used for imaging patients with chronic liver disease. SWE offers the advantage of a real-time image of liver anatomy, while also providing a color coded map and quantitative measurement of liver stiffness, making it an important parameter to enhance liver diagnostics. About 100 international publications have demonstrated the reliability and effectiveness of SuperSonic Imagine's SWE in this area. In addition, eight abstracts accepted by AASLD reporting results from clinical research studies using SuperSonic's imagine's technology will be presented as posters during the meeting: Diagnostic accuracy of Shear Wave Elastography for the assessment of liver stiffness in pediatric patients with fatty liver disease (Abstract #546) Matteo Garcovich et al. #654 Role of shear wave elastography in patients on high dose methotrexate: A prospective study (Abstract 654) Robert S. Rahimi et al. Regression of Liver Fibrosis assessed by non-invasive methods in Patients with Chronic Hepatitis C who Achieved Sustained Virologic Response after DAAs Treatment (Abstract 824) Yana Davidov et al. Prospective Comparison between Transient Elastography, Supersonic Shear Imaging, and ARFI Imaging for Predicting Fibrosis in Subjects with NAFLD (Abstract 1058) Won Kim et al. Improvement in Non-Invasive Hepatic Parameters of Nonalcoholic Fatty Liver Disease in Obese Uncontrolled Type 2 Diabetes Mellitus Patients who underwent Endoscopic Duodenal-Jejunal Bypass Liner (Endobarrier) Implantation (Abstract 1105) Oranit Cohen-Ezra et al. Probiotics do not improve hepatic outcomes after Laparoscopic Sleeve Gastrectomy surgery: a randomized clinical trial (Abstract 1123) Shiri Sherf Dagan et al. 2-dimensional shear wave elastography rather than HVPG significantly improves MELD-Na to predict survival in decompensated cirrhosis patients (Abstract 1406) Maja Thiele et al. "SuperSonic Imagine's dedication to advancing the evaluation of chronic liver disease has enabled us to develop innovative solutions such as image-guided ShearWave Elastography, an accurate, easy-to-use and pain-free liver exam," explained SuperSonic Imagine Founder and Chief Innovation Officer Jacques Souquet. "We are excited to share this technology's capabilities at The Liver Meeting, where we know hepatologists from around the world will share our enthusiasm for the non-invasive quantification of liver stiffness." SSI will be exhibiting at booth #313 throughout The Liver Meeting. The Liver Meeting® is a registered trademark of the American Association for the Study of Liver Diseases. Founded in 2005 and based in Aix-en-Provence (France), SuperSonic Imagine is a company specializing in medical imaging. The company designs, develops and markets a revolutionary ultrasound system, Aixplorer®, with an UltraFast™ platform that can acquire images 200 times faster than conventional ultrasound systems. In addition to providing exceptional image quality, this unique technology is the foundation of several innovations which have changed the paradigm of ultrasound imaging: ShearWave™ Elastography (SWE™), UltraFast™ Doppler and more recently Angio PL.U.S* - Planewave UltraSensitive™ Imaging. ShearWave Elastography allows physicians to visualize and analyze the stiffness of tissue in a real-time, reliable, reproducible and non-invasive manner. This criteria has become an important parameter in diagnosing potentially malignant tissue or other diseased tissue. As of today, over 300 peer-reviewed publications have demonstrated the value of SWE for the clinical management of patients with a wide range of diseases. UltraFast Doppler combines Color Flow Imaging and Pulsed Wave Doppler into one simple exam, providing physicians with exam results simultaneously and helping to increase patient throughput. The latest innovation, Angio PL.U.S, provides a new level of microvascular imaging through significantly improved color sensitivity and spatial resolution while maintaining exceptional 2D imaging. SuperSonic Imagine has been granted regulatory clearances for the commercialization of Aixplorer in key global markets. SuperSonic Imagine is a listed company since April 2014 on the Euronext, symbol SSI. For more information about SuperSonic Imagine, please go to www.supersonicimagine.com.


HOUSTON, Feb. 14, 2017 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (PLx), a late-stage specialty pharmaceutical company developing next-generation nonsteroidal anti-inflammatory drugs and other pharmaceutical agents today announced that the results of a 40-subject pharmacokinetic/pharmacodynamic (PK/PD) trial of Aspertec™, a novel, patent-protected, lipid-based aspirin product, have been published by the prestigious, peer-reviewed Journal of the American College of Cardiology (JACC). The publication, entitled “Enteric Coating and Aspirin Nonresponsiveness in Patients with Type 2 Diabetes Mellitus,” describes results of the study, which evaluated Aspertec 325 mg versus two commercially-available 325 mg aspirin products: plain (uncoated) and delayed-release, safety-coated (enteric-coated or EC) aspirin, over 72 hours. “This study contributes to the growing body of data on the antiplatelet activity of different aspirin formulations within 72 hours of starting an aspirin regimen. The information gathered from this PK/PD trial suggests that, for these patients, there was, initially, substantial variability in antiplatelet activity depending on the dose form of aspirin administered,” stated Deepak L. Bhatt, MD, MPH, lead author of the study and Executive Director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital and Professor of Medicine at the Harvard Medical School. “We are very encouraged by the published results of this study and the potential of our novel lipid-based, liquid-filled Aspertec capsule to provide reliable and predictable antiplatelet activity. We believe Aspertec, with multiple potential benefits as a fast, predictable and reliable antiplatelet agent, will provide an important treatment option for prescribers in determining the optimal aspirin formulation for use as the foundational medicine by their secondary prevention and high-risk primary prevention patients,” stated Natasha Giordano, President and Chief Executive Officer of PLx. The article is available online at http://www.onlinejacc.org/content/early/2017/01/05/j.jacc.2016.11.050. JACC publishes the highest quality articles highlighting all aspects of cardiovascular health and disease. With a current impact factor of 17.759, it is one of the most influential journals in the field of cardiology. About Aspertec Aspertec is an approved aspirin product developed to provide reliable and predictable antiplatelet activity.  PLx is focused on completing manufacturing scale-up and label finalization for Aspertec 325 mg aspirin dosage form and preparing a supplemental new drug application (sNDA) for Aspertec 81 mg maintenance dose form. About PLx PLx Pharma Inc. is a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide safe and effective aspirin products. The PLxGuard delivery system works by targeting delivery of active pharmaceutical ingredients (API) to various portions of the GI tract. PLx believes this has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce acute gastrointestinal (GI) side effects—including erosions, ulcers and bleeding—associated with aspirin and ibuprofen, and potentially other drugs. On December 22, 2016, PLx announced that it had entered into a merger agreement with Dipexium Pharmaceuticals, Inc. (NASDAQ:DPRX). Following the closing of the merger—which is subject to a number of conditions precedent, including approval of both PLx and Dipexium stockholders—it is expected that Dipexium will be renamed “PLx Pharma Inc.” and will operate under the leadership of the PLx management team. To learn more about PLx and its pipeline, please visit www.plxpharma.com. Forward-Looking Statements Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the prospects for commercializing or selling any products or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to PLx may identify forward-looking statements. PLx cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by PLx to secure and maintain relationships with collaborators; risks relating to clinical trials; risks relating to the commercialization, if any, of PLx’s proposed product candidates (such as marketing, regulatory, product liability, supply, competition, and other risks); dependence on the efforts of third parties; dependence on intellectual property; risks that PLx may lack the financial resources and access to capital to fund proposed operations; and risks that the proposed merger with Dipexium may not be consummated. The forward-looking statements represent PLx’s estimate as of the date hereof only, and PLx specifically disclaims any duty or obligation to update forward-looking statements. Citation for this article: Bhatt DL et al. Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients. Journal of the American College of Cardiology Jan 2017, 23269; DOI: 10.1016/j.jacc.2016.11.050


This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announced new phase 3b trial (DUAL VII) results with Xultophy® (IDegLira). Xultophy® is a once-daily, single injection fixed combination of a long-acting basal insulin (insulin degludec) and a glucagon-like peptide-1 (GLP-1) receptor agonist (liraglutide).[1] The open-label trial investigated the efficacy and safety of Xultophy® compared with insulin glargine U100 in combination with insulin aspart at all main meals, after 26 weeks of treatment in 506 adults with type 2 diabetes.[2],[3] The trial successfully achieved its objective by demonstrating that treatment with Xultophy® is non-inferior to insulin glargine U100 in combination with insulin aspart with regards to lowering of HbA . From a mean baseline HbA of 8.2%, both patient groups reached a similar HbA level of 6.7% after 26 weeks of treatment. At the end of the trial, people treated with Xultophy® required 40.1 units compared to a total of 84.6 units of insulin for people treated with insulin glargine U100 in combination with insulin aspart.[3] People treated with Xultophy® showed a superior reduction of 89% in the rate of severe or blood glucose confirmed symptomatic hypoglycaemic episodes compared to insulin glargine U100 in combination with insulin aspart. Furthermore, from a mean baseline body weight of 87.7 kg, people treated with Xultophy® experienced weight loss of 0.9 kg compared with weight gain of 2.6 kg for people treated with the basal-bolus regimen; a superior weight difference of -3.6 kg.[3] "We are excited about the results of DUAL VII, showing the important benefits Xultophy® offers for people inadequately controlled on insulin glargine U100 as an alternative to intensification with basal-bolus therapy" said Mads Krogsgaard Thomsen, executive vice president and chief science officer, Novo Nordisk A/S. "Xultophy® shows these impressive results, including reduction in hypoglycaemia and body weight, with a much lower dose compared to insulin glargine U100 in combination with insulin aspart at the end of the study." The safety profile of Xultophy® in DUAL VII was generally consistent with previous Xultophy® clinical trials.[3] The complete trial results will be presented in the first half of 2017. Xultophy® is a once-daily single injection fixed combination of long-acting insulin degludec (Tresiba®) and the GLP-1 receptor agonist liraglutide (Victoza®). The maximum dose of Xultophy® is 50 dose steps (equivalent to 50 units of insulin degludec and 1.8 mg of liraglutide).[1] Xultophy® has been investigated in seven trials in the DUAL clinical trial programme, encompassing more than 4,000 people with type 2 diabetes. Phase 3b trials are still ongoing. On 21 November 2016, Xultophy® was approved by the FDA under the brand name Xultophy® 100/3.6.[4] On 18 September 2014, Xultophy® was granted marketing authorisation by the European Commission and approved in Switzerland on 12 September 2014.[1],[5] DUAL VII was a phase 3b, 26-week, randomised, open-label, multicentre trial conducted in 12 countries with 506 patients.[2],[3] The trial was designed to investigate the safety and efficacy of Xultophy® vs basal-bolus therapy in adults with type 2 diabetes previously treated with insulin glargine U100 and metformin.[2] Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,600 people in 75 countries and markets its products in more than 180 countries. For more information, visit  novonordisk.com, Facebook, Twitter, LinkedIn, YouTube 1. EMA. Xultophy® summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002647/WC500177657.pdf Last accessed: November 2016. 2. ClinicalTrials.gov. A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus. Available at: https://clinicaltrials.gov/ct2/show/NCT02420262?term=ideglira%2C+basal-bolus&rank=1 Last accessed November 2016. 4. Novo Nordisk. Novo Nordisk receives US FDA approval for Xultophy® 100/3.6. Available at:  http://www.novonordisk.com/bin/getPDF.2058006.pdf Last accessed November 2016.


This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announced new phase 3b trial (DUAL VII) results with Xultophy® (IDegLira). Xultophy® is a once-daily, single injection fixed combination of a long-acting basal insulin (insulin degludec) and a glucagon-like peptide-1 (GLP-1) receptor agonist (liraglutide).[1] The open-label trial investigated the efficacy and safety of Xultophy® compared with insulin glargine U100 in combination with insulin aspart at all main meals, after 26 weeks of treatment in 506 adults with type 2 diabetes.[2],[3] The trial successfully achieved its objective by demonstrating that treatment with Xultophy® is non-inferior to insulin glargine U100 in combination with insulin aspart with regards to lowering of HbA . From a mean baseline HbA of 8.2%, both patient groups reached a similar HbA level of 6.7% after 26 weeks of treatment. At the end of the trial, people treated with Xultophy® required 40.1 units compared to a total of 84.6 units of insulin for people treated with insulin glargine U100 in combination with insulin aspart.[3] People treated with Xultophy® showed a superior reduction of 89% in the rate of severe or blood glucose confirmed symptomatic hypoglycaemic episodes compared to insulin glargine U100 in combination with insulin aspart. Furthermore, from a mean baseline body weight of 87.7 kg, people treated with Xultophy® experienced weight loss of 0.9 kg compared with weight gain of 2.6 kg for people treated with the basal-bolus regimen; a superior weight difference of -3.6 kg.[3] "We are excited about the results of DUAL VII, showing the important benefits Xultophy® offers for people inadequately controlled on insulin glargine U100 as an alternative to intensification with basal-bolus therapy" said Mads Krogsgaard Thomsen, executive vice president and chief science officer, Novo Nordisk A/S. "Xultophy® shows these impressive results, including reduction in hypoglycaemia and body weight, with a much lower dose compared to insulin glargine U100 in combination with insulin aspart at the end of the study." The safety profile of Xultophy® in DUAL VII was generally consistent with previous Xultophy® clinical trials.[3] The complete trial results will be presented in the first half of 2017. Xultophy® is a once-daily single injection fixed combination of long-acting insulin degludec (Tresiba®) and the GLP-1 receptor agonist liraglutide (Victoza®). The maximum dose of Xultophy® is 50 dose steps (equivalent to 50 units of insulin degludec and 1.8 mg of liraglutide).[1] Xultophy® has been investigated in seven trials in the DUAL clinical trial programme, encompassing more than 4,000 people with type 2 diabetes. Phase 3b trials are still ongoing. On 21 November 2016, Xultophy® was approved by the FDA under the brand name Xultophy® 100/3.6.[4] On 18 September 2014, Xultophy® was granted marketing authorisation by the European Commission and approved in Switzerland on 12 September 2014.[1],[5] DUAL VII was a phase 3b, 26-week, randomised, open-label, multicentre trial conducted in 12 countries with 506 patients.[2],[3] The trial was designed to investigate the safety and efficacy of Xultophy® vs basal-bolus therapy in adults with type 2 diabetes previously treated with insulin glargine U100 and metformin.[2] Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,600 people in 75 countries and markets its products in more than 180 countries. For more information, visit  novonordisk.com, Facebook, Twitter, LinkedIn, YouTube 1. EMA. Xultophy® summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002647/WC500177657.pdf Last accessed: November 2016. 2. ClinicalTrials.gov. A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus. Available at: https://clinicaltrials.gov/ct2/show/NCT02420262?term=ideglira%2C+basal-bolus&rank=1 Last accessed November 2016. 4. Novo Nordisk. Novo Nordisk receives US FDA approval for Xultophy® 100/3.6. Available at:  http://www.novonordisk.com/bin/getPDF.2058006.pdf Last accessed November 2016.


News Article | February 20, 2017
Site: www.businesswire.com

ATLANTA--(BUSINESS WIRE)--During next week’s HIMSS Annual Conference & Exhibition in Orlando, Fla., Brightree®, a leading provider of cloud-based software to improve clinical and business performance of post-acute care companies, will join CommonWell Health Alliance®, a not-for-profit trade association focused on fostering nationwide health data exchange, and Cerner, a global leader in health care technology, to demonstrate an innovative, person-centric interoperability experience. The demonstration will take place at booth #9000 during the HIMSS Interoperability Showcase: Where IT Connects Everything. The Interoperability Showcase is a premier experience for HIMSS attendees that demonstrates health information technology data exchange through production-ready standards, on: Brightree, a Contributor Member of CommonWell Health Alliance, will be part of the CommonWell Care Transitions use case demonstration, where attendees will follow a hypothetical healthcare patient (named Gloria) with Type 2 Diabetes Mellitus. The demonstration will show the process of her care transition from acute to home care to primary care using Direct Secure Messaging and CommonWell Health Alliance interoperability services. “The future of healthcare and value-based reimbursement requires patient-centric interoperability,” said Jitin Asnaani, executive director of CommonWell Health Alliance. “To optimize care delivery, we must get the data to follow the patient. As our first post-acute focused vendor, Brightree has championed use case extensions to bring this level of interoperability to post-acute providers. By connecting to the CommonWell network, Brightree will enable access to thousands of health care delivery sites and millions of patient records on behalf of its providers. This is a game-changer for post-acute care delivery and patients who are being treated in the post-acute space.” Brightree will demonstrate how its solutions and services are integrated into the system of care by using direct secure messaging of clinical information to initiate a referral and CommonWell network services to augment the referral and supply insight to the patient’s other care providers. “This demonstration will showcase how interoperability is turning a patient’s experience into a smooth transition of care,” said Gary Bartlett, Brightree product manager, interoperability. “Improving how information is recorded, sent and received improves patient outcomes, which is important for the patient and for the provider as the industry shifts to a value-based reimbursement model.” Brightree represents one part of the patient’s three-part interoperability journey, which includes acute and ambulatory care settings represented by Cerner, a Founding Member of CommonWell. The organizations will show attendees how they connect and work together at different areas of the health care continuum to help a patient through various stages of disease management. “Each step utilizes the power of interoperability to show how we can work together to improve patient care,” said Nick Knowlton, Brightree vice president, business development. “We are thrilled to be working with these organizations to help improve care transitions and demonstrate the overall value proposition to the post-acute and broader healthcare world.” Also at HIMSS, Brightree CEO Matt Mellott will be featured on CommonWell TV on Feb. 21, where he will share his insight on interoperability, the healthcare industry, the company’s partnership with CommonWell and other topics. “We strive to provide our customers with the best tools possible to care for their patients, and we are excited to demonstrate our interoperability solutions to the health care industry,” said Mellott. Brightree is a leading provider of cloud-based software to improve clinical and business performance of post-acute care companies. Ranked one of the top 100 healthcare IT companies in the U.S., Brightree serves more than 2,200 organizations in the HME, home health, hospice, orthotic and prosthetic, HME pharmacy, home infusion, and rehabilitation home care segments. For more information, visit www.brightree.com or call 1.888.598.7797.


A new report from business intelligence provider GBI Research - Frontier Pharma: Type 2 Diabetes Mellitus - states that the increasing demand for type 2 diabetes mellitus (T2DM) therapeutics, caused by rising prevalence of the disease, has resulted in a large and competitive market landscape. There are a number of drugs competing for different market segments, across multiple lines of therapy. The emergence over the past decade of glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase 4 inhibitors and sodium-glucose cotransporter 2 inhibitors has intensified competition. These new drug classes have been highly commercially successful and are now well established within the T2DM treatment algorithm. The leading products within these drug classes are Novo Nordisk's Victoza, Merck's Januvia, and Janssen's Invokana, respectively. In 2015, these drugs generated $2.7 billion, $4.3 billion, and $1.6 billion, respectively. Analyst Fiona Chisholm notes: "In spite of recent developments, there are still significant unmet needs for T2DM. Treatment regimens are often complex, and many drugs have limited long-term efficacy and side effects that are particularly undesirable for the T2DM patient population, such as increased cardiovascular risk factors or weight gain. "Alongside the rapidly expanding prevalence population, this ensures that sustained investment in T2DM product innovation continues to be an attractive commercial prospect. Indeed, with 591 products in development, T2DM pipeline activity is very high in comparison to other related indications within metabolic disorders such as obesity and type 1 diabetes mellitus, which have 254 and 244 active products in development, respectively." T2DM therapeutics can often attract high values in licensing or co-development strategic consolidations. GBI Research's analysis of licensing and co-development deals relating to T2DM therapeutics since 2006 has identified aggregate deal values of $9.2 billion and $9.5 billion, respectively, for deals with disclosed deal values. "Despite this, the majority of first-in-class products in development for T2DM have no disclosed involvement in previous licensing or co-development. Among these products, the range of molecular targets is relatively wide, providing ample and diverse opportunities for potential investors. Entering into a licensing or co-development deal can have significant benefits for both parties, including shared product development risks, financial and R&D resource support, and portfolio or geographical expansion," Chisholm concludes. Sample pages of GBI Research's report Frontier Pharma: Type 2 Diabetes Mellitus are available upon request GBI Research is a leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key healthcare industry influencers to ensure you stay up-to-date with the latest market trends. For more information about our offerings, please contact us on: Connect with GBI Research on social media for the latest healthcare market updates:


CITY OF INDUSTRY, CA--(Marketwired - Mar 2, 2017) - Marina Biotech, Inc. ( : MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, today announced that new data related to its IT-102 and IT-103 will be presented at the 7th International Conference on Fixed Combination in the Treatment of Hypertension, Dyslipidemia and Diabetes Mellitus in Cannes, France on March 2-5, 2017. Dr. Vuong Trieu, Chairman of the Board for Marina Biotech, will present a poster on the clinical development of Celecoxib-Lisinopril FDC (IT-102) and Celecoxib-Olmesartan FDC (IT-103) against combined arthritis/hypertension. This is a retrospective study that uses two patient level data sources over a three year period. These FDCs are being developed as next generation Celecoxib -- Celecoxib without Celecoxib drug-induced edema -- as inhibitor of the beta-catenin/COX-2 axis for the treatment of pain, arthritis, and cancers such as FAP and CRC. "These presentations will unveil how Marina Biotech, together with Autotelic Inc., is leveraging FDCs to treat the often neglected disease intersections, as well as improving already safe drugs for novel indications, especially cancer," stated Joseph Ramelli, CEO of Marina Biotech. About Marina Biotech Marina Biotech is a biotechnology company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension, and cancer. Our pipeline includes combination therapies of oligonucleotide-based therapeutics and small molecules. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome). By its merger with IthenaPharma, Marina Biotech recently acquired IT-102/IT-103 -- next generation celecoxib -- which will be developed together with CEQ508 as a therapeutic enhancer for therapies against FAP and CRC. IT-102/IT-103 are also being developed for the treatment of combined arthritis/ hypertension and treatment of pain requiring high dose of celecoxib. Additional information about Marina Biotech is available at http://www.marinabio.com. Marina Biotech Forward-Looking Statements Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Marina Biotech to successfully integrate its business operations with those of IthenaPharma; (ii) the ability of Marina Biotech to obtain funding to support its clinical development; (iii) the ability of Marina Biotech to attract and/or maintain manufacturing, research, development and commercialization partners; (iv) the ability of Marina Biotech and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (v) the ability of Marina Biotech and/or a partner to obtain required governmental approvals; and (vi) the ability of Marina Biotech and/or a partner to develop and commercialize products prior to, and that can compete favorably with those of, competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Marina Biotech's most recent filings with the Securities and Exchange Commission. Marina Biotech assumes no obligation to update or supplement forward-looking statements because of subsequent events.


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Implantable Infusion Pumps Market Analysis & Trends- Application (Cancer Treatment, Cancer Pain, Noncancer Pain, Spasticity, Analgesia, Mixed Sarcoma and Skin Cancers, Gastric Cancer and Diabetes Mellitus) - Forecast to 2025" report to their offering. The Global Implantable Infusion Pumps Market is poised to grow at a CAGR of around 6.3% over the next decade to reach approximately $14.33 billion by 2025. Some o


News Article | December 23, 2016
Site: www.prlog.org

One of the most commonly occurring diseases in the adults these days is diabetes which is classified into two types namely Insipidus and Mellitus which is also known as type-2 diabetes.


LONDON, December 1, 2016 /PRNewswire/ -- A new Analyst View from business intelligence provider GBI Research - Repurposing Type 2 Diabetes Mellitus Drugs for Alzheimer's Disease - states that recent findings have shown that type 2 diabetes mellitus (T2DM) drugs could be used to...

Loading Mellitus collaborators
Loading Mellitus collaborators